SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Ullenhag Gustav)
 

Search: WFRF:(Ullenhag Gustav) > Elevated Levels of ...

Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay

Blokzijl, Andries (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab
Chen, Lei, 1985- (author)
Uppsala universitet,Molekylära verktyg,Science for Life Laboratory, SciLifeLab
Gustafsdottir, Sigrun M. (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab
show more...
Vuu, Jimmy (author)
Uppsala universitet,Institutionen för immunologi, genetik och patologi
Ullenhag, Gustav (author)
Uppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap
Kämpe, Olle (author)
Karolinska Institutet,Uppsala universitet,Autoimmunitet
Landegren, Ulf (author)
Uppsala universitet,Molekylära verktyg,Science for Life Laboratory, SciLifeLab
Kamali-Moghaddam, Masood (author)
Uppsala universitet,Molekylära verktyg
Hedstrand, Håkan (author)
Uppsala universitet,Dermatologi och venereologi
show less...
 (creator_code:org_t)
2016-04-25
2016
English.
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 11:4
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BackgroundThe diagnosis of malignant melanoma currently relies on clinical inspection of the skin surface and on the histopathological status of the excised tumor. The serum marker S100B is used for prognostic estimates at later stages of the disease, but analyses are marred by false positives and inadequate sensitivity in predicting relapsing disorder.ObjectivesTo investigate SOX10 as a potential biomarker for melanoma and vitiligo.MethodsIn this study we have applied proximity ligation assay (PLA) to detect the transcription factor SOX10 as a possible serum marker for melanoma. We studied a cohort of 110 melanoma patients. We further investigated a second cohort of 85 patients with vitiligo, which is a disease that also affects melanocytes.ResultsThe specificity of the SOX10 assay in serum was high, with only 1% of healthy blood donors being positive. In contrast, elevated serum SOX10 was found with high frequency among vitiligo and melanoma patients. In patients with metastases, lack of SOX10 detection was associated with treatment benefit. In two responding patients, a change from SOX10 positivity to undetectable levels was seen before the response was evident clinically.ConclusionsWe show for the first time that SOX10 represents a promising new serum melanoma marker for detection of early stage disease, complementing the established S100B marker. Our findings imply that SOX10 can be used to monitor responses to treatment and to assess if the treatment is of benefit at stages earlier than what is possible radiologically.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)

Keyword

sox10 proximity ligation assay

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view